Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis

Wei Fan Hsu; Chi Yi Chen; Kuo Chih Tseng; Hsueh Chou Lai; Hsing Tao Kuo; Chao Hung Hung; Shui Yi Tung; Jing Houng Wang; Jyh Jou Chen; Pei Lun Lee; Rong Nan Chien; Chun Yen Lin; Chi Chieh Yang; Gin Ho Lo; Chi Ming Tai; Chih Wen Lin; Jia Horng Kao; Chun Jen Liu; Chen Hua Liu; Sheng Lei Yan; Ming Jong Bair; Wei Wen Su; Cheng Hsin Chu; Chih Jen Chen; Ching Chu Lo; Pin Nan Cheng; Yen Cheng Chiu; Chia Chi Wang; Jin Shiung Cheng; Wei Lun Tsai; Han Chieh Lin; Yi Hsiang Huang; Pei Chien Tsai; Jee Fu Huang; Chia Yen Dai; Wan Long Chuang; Ming Lung Yu; Cheng Yuan Peng

doi:10.1038/s41598-020-61991-3

Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis

Wei Fan Hsu, Chi Yi Chen, Kuo Chih Tseng, Hsueh Chou Lai, Hsing Tao Kuo, Chao Hung Hung, Shui Yi Tung, Jing Houng Wang, Jyh Jou Chen, Pei Lun Lee, Rong Nan Chien, Chun Yen Lin, Chi Chieh Yang, Gin Ho Lo, Chi Ming Tai, Chih Wen Lin, Jia Horng Kao, Chun Jen Liu, Chen Hua Liu, Sheng Lei YanMing Jong Bair, Wei Wen Su, Cheng Hsin Chu, Chih Jen Chen, Ching Chu Lo, Pin Nan Cheng, Yen Cheng Chiu, Chia Chi Wang, Jin Shiung Cheng, Wei Lun Tsai, Han Chieh Lin, Yi Hsiang Huang, Pei Chien Tsai, Jee Fu Huang, Chia Yen Dai, Wan Long Chuang, Ming Lung Yu, Cheng Yuan Peng^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

5 Scopus citations

Abstract

In patients with chronic hepatitis C (CHC), the effects of baseline characteristics, virological profiles, and therapeutic outcome to pegylated interferon plus ribavirin (PR) therapy on autoimmune diseases are unknown. Taiwanese Chronic Hepatitis C Cohort is a nationwide hepatitis C virus registry cohort comprising 23 hospitals of Taiwan. A total of 12,770 CHC patients receiving PR therapy for at least 4 weeks between January 2003 and December 2015 were enrolled and their data were linked to the Taiwan National Health Insurance Research Database for studying the development of 10 autoimmune diseases. The mean follow-up duration was 5.3 ± 2.9 years with a total of 67,930 person-years, and the annual incidence of systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) was 0.03%. Other autoimmune diseases were not assessable due to few events. Body mass index ≥24 kg/m² was an independent predictor of the low incidence of SLE or RA (hazard ratio 0.40, 95% confidence interval 0.17–0.93, p = 0.034). A sustained virological response (SVR) to PR therapy was not associated with the low incidence of SLE or RA in any subgroup analysis. CHC patients achieving SVR to PR therapy did not exhibit an impact on the incidence of SLE or RA compared with non-SVR patients.

Original language	English
Article number	5372
Journal	Scientific Reports
Volume	10
Issue number	1
DOIs	https://doi.org/10.1038/s41598-020-61991-3
State	Published - 01 12 2020
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2020, The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41598-020-61991-3

Cite this

Hsu, W. F., Chen, C. Y., Tseng, K. C., Lai, H. C., Kuo, H. T., Hung, C. H., Tung, S. Y., Wang, J. H., Chen, J. J., Lee, P. L., Chien, R. N., Lin, C. Y., Yang, C. C., Lo, G. H., Tai, C. M., Lin, C. W., Kao, J. H., Liu, C. J., Liu, C. H., ... Peng, C. Y. (2020). Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis. Scientific Reports, 10(1), Article 5372. https://doi.org/10.1038/s41598-020-61991-3

@article{930c7a7828a94d44a9e2aa23236d1a01,

title = "Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis",

abstract = "In patients with chronic hepatitis C (CHC), the effects of baseline characteristics, virological profiles, and therapeutic outcome to pegylated interferon plus ribavirin (PR) therapy on autoimmune diseases are unknown. Taiwanese Chronic Hepatitis C Cohort is a nationwide hepatitis C virus registry cohort comprising 23 hospitals of Taiwan. A total of 12,770 CHC patients receiving PR therapy for at least 4 weeks between January 2003 and December 2015 were enrolled and their data were linked to the Taiwan National Health Insurance Research Database for studying the development of 10 autoimmune diseases. The mean follow-up duration was 5.3 ± 2.9 years with a total of 67,930 person-years, and the annual incidence of systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) was 0.03%. Other autoimmune diseases were not assessable due to few events. Body mass index ≥24 kg/m2 was an independent predictor of the low incidence of SLE or RA (hazard ratio 0.40, 95% confidence interval 0.17–0.93, p = 0.034). A sustained virological response (SVR) to PR therapy was not associated with the low incidence of SLE or RA in any subgroup analysis. CHC patients achieving SVR to PR therapy did not exhibit an impact on the incidence of SLE or RA compared with non-SVR patients.",

author = "Hsu, {Wei Fan} and Chen, {Chi Yi} and Tseng, {Kuo Chih} and Lai, {Hsueh Chou} and Kuo, {Hsing Tao} and Hung, {Chao Hung} and Tung, {Shui Yi} and Wang, {Jing Houng} and Chen, {Jyh Jou} and Lee, {Pei Lun} and Chien, {Rong Nan} and Lin, {Chun Yen} and Yang, {Chi Chieh} and Lo, {Gin Ho} and Tai, {Chi Ming} and Lin, {Chih Wen} and Kao, {Jia Horng} and Liu, {Chun Jen} and Liu, {Chen Hua} and Yan, {Sheng Lei} and Bair, {Ming Jong} and Su, {Wei Wen} and Chu, {Cheng Hsin} and Chen, {Chih Jen} and Lo, {Ching Chu} and Cheng, {Pin Nan} and Chiu, {Yen Cheng} and Wang, {Chia Chi} and Cheng, {Jin Shiung} and Tsai, {Wei Lun} and Lin, {Han Chieh} and Huang, {Yi Hsiang} and Tsai, {Pei Chien} and Huang, {Jee Fu} and Dai, {Chia Yen} and Chuang, {Wan Long} and Yu, {Ming Lung} and Peng, {Cheng Yuan}",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = dec,

day = "1",

doi = "10.1038/s41598-020-61991-3",

language = "英语",

volume = "10",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Research",

number = "1",

}

Hsu, WF, Chen, CY, Tseng, KC, Lai, HC, Kuo, HT, Hung, CH, Tung, SY, Wang, JH, Chen, JJ, Lee, PL, Chien, RN, Lin, CY, Yang, CC, Lo, GH, Tai, CM, Lin, CW, Kao, JH, Liu, CJ, Liu, CH, Yan, SL, Bair, MJ, Su, WW, Chu, CH, Chen, CJ, Lo, CC, Cheng, PN, Chiu, YC, Wang, CC, Cheng, JS, Tsai, WL, Lin, HC, Huang, YH, Tsai, PC, Huang, JF, Dai, CY, Chuang, WL, Yu, ML & Peng, CY 2020, 'Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis', Scientific Reports, vol. 10, no. 1, 5372. https://doi.org/10.1038/s41598-020-61991-3

TY - JOUR

T1 - Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis

AU - Hsu, Wei Fan

AU - Chen, Chi Yi

AU - Tseng, Kuo Chih

AU - Lai, Hsueh Chou

AU - Kuo, Hsing Tao

AU - Hung, Chao Hung

AU - Tung, Shui Yi

AU - Wang, Jing Houng

AU - Chen, Jyh Jou

AU - Lee, Pei Lun

AU - Chien, Rong Nan

AU - Lin, Chun Yen

AU - Yang, Chi Chieh

AU - Lo, Gin Ho

AU - Tai, Chi Ming

AU - Lin, Chih Wen

AU - Kao, Jia Horng

AU - Liu, Chun Jen

AU - Liu, Chen Hua

AU - Yan, Sheng Lei

AU - Bair, Ming Jong

AU - Su, Wei Wen

AU - Chu, Cheng Hsin

AU - Chen, Chih Jen

AU - Lo, Ching Chu

AU - Cheng, Pin Nan

AU - Chiu, Yen Cheng

AU - Wang, Chia Chi

AU - Cheng, Jin Shiung

AU - Tsai, Wei Lun

AU - Lin, Han Chieh

AU - Huang, Yi Hsiang

AU - Tsai, Pei Chien

AU - Huang, Jee Fu

AU - Dai, Chia Yen

AU - Chuang, Wan Long

AU - Yu, Ming Lung

AU - Peng, Cheng Yuan

PY - 2020/12/1

Y1 - 2020/12/1

N2 - In patients with chronic hepatitis C (CHC), the effects of baseline characteristics, virological profiles, and therapeutic outcome to pegylated interferon plus ribavirin (PR) therapy on autoimmune diseases are unknown. Taiwanese Chronic Hepatitis C Cohort is a nationwide hepatitis C virus registry cohort comprising 23 hospitals of Taiwan. A total of 12,770 CHC patients receiving PR therapy for at least 4 weeks between January 2003 and December 2015 were enrolled and their data were linked to the Taiwan National Health Insurance Research Database for studying the development of 10 autoimmune diseases. The mean follow-up duration was 5.3 ± 2.9 years with a total of 67,930 person-years, and the annual incidence of systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) was 0.03%. Other autoimmune diseases were not assessable due to few events. Body mass index ≥24 kg/m2 was an independent predictor of the low incidence of SLE or RA (hazard ratio 0.40, 95% confidence interval 0.17–0.93, p = 0.034). A sustained virological response (SVR) to PR therapy was not associated with the low incidence of SLE or RA in any subgroup analysis. CHC patients achieving SVR to PR therapy did not exhibit an impact on the incidence of SLE or RA compared with non-SVR patients.

AB - In patients with chronic hepatitis C (CHC), the effects of baseline characteristics, virological profiles, and therapeutic outcome to pegylated interferon plus ribavirin (PR) therapy on autoimmune diseases are unknown. Taiwanese Chronic Hepatitis C Cohort is a nationwide hepatitis C virus registry cohort comprising 23 hospitals of Taiwan. A total of 12,770 CHC patients receiving PR therapy for at least 4 weeks between January 2003 and December 2015 were enrolled and their data were linked to the Taiwan National Health Insurance Research Database for studying the development of 10 autoimmune diseases. The mean follow-up duration was 5.3 ± 2.9 years with a total of 67,930 person-years, and the annual incidence of systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) was 0.03%. Other autoimmune diseases were not assessable due to few events. Body mass index ≥24 kg/m2 was an independent predictor of the low incidence of SLE or RA (hazard ratio 0.40, 95% confidence interval 0.17–0.93, p = 0.034). A sustained virological response (SVR) to PR therapy was not associated with the low incidence of SLE or RA in any subgroup analysis. CHC patients achieving SVR to PR therapy did not exhibit an impact on the incidence of SLE or RA compared with non-SVR patients.

UR - http://www.scopus.com/inward/record.url?scp=85082470585&partnerID=8YFLogxK

U2 - 10.1038/s41598-020-61991-3

DO - 10.1038/s41598-020-61991-3

M3 - 文章

C2 - 32214132

AN - SCOPUS:85082470585

SN - 2045-2322

VL - 10

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 5372

ER -

Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this